Abbott Laboratories (ABT) 41.97 $ABT
The New #64 Most Shorted S&P 500 Component: Abbott Laboratories
MarketNewsVideo.com - Wed Jul 13, 3:27PM CDT
The most recent short interest data has been released for the 06/30/2016 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the S&P 500 by "days to cover." There are a...
ABT: 41.97 (-0.50)
Pfizer (PFE) Gets FDA Nod for Label Expansion of Prevnar 13
Zacks Equity Research - Zacks Investment Research - Wed Jul 13, 8:25AM CDT
Pfizer Inc. (PFE) announced that the FDA has approved a label expansion of vaccine Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]).
ABT: 41.97 (-0.50), JNJ: 123.00 (+0.08), PFE: 36.31 (+0.07)
Pfizer Reports Positive Data on Kidney Cancer Drug Sutent
Zacks Equity Research - Zacks Investment Research - Mon Jul 11, 8:23AM CDT
Pfizer Inc. (PFE) announced positive results from the phase III study, S-TRAC, on kidney cancer drug Sutent.
ABT: 41.97 (-0.50), PFE: 36.31 (+0.07), EXEL: 8.04 (-0.10), NVS: 82.03 (+0.35)
Shire (SHPG) Gets EU Nod for Label Expansion of Revestive
Zacks Equity Research - Zacks Investment Research - Fri Jul 08, 5:36PM CDT
Shire plc (SHPG) announced that the European Commission has granted an extension of the market authorization for its gastrointestinal drug (GI) Revestive for use in the pediatric population.
ABT: 41.97 (-0.50), JNJ: 123.00 (+0.08), SHPG: 192.49 (-2.82), PFE: 36.31 (+0.07)
Top 7 Research Reports for July 8, 2016
Sheraz Mian - Zacks Investment Research - Fri Jul 08, 12:16PM CDT
Top 7 Research Reports for July 8, 2016
ABT: 41.97 (-0.50), WBA: 81.77 (+0.55), IR: 67.52 (+0.58), MCD: 122.82 (+0.57), LOW: 81.65 (-1.29), BMY: 76.58 (+0.38)
Abbott Labs' Absorb Stent Gets Regulatory Approval in U.S.
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 8:58AM CDT
Abbott Laboratories (ABT) received a major boost when the FDA approved its bioresorbable heart stent, Absorb, for the treatment of coronary artery disease in the U.S.
ABT: 41.97 (-0.50), JNJ: 123.00 (+0.08), PFE: 36.31 (+0.07), STJ: 80.45 (-0.43)
Medical Device Consolidation Frenzy: Here's How to Play it
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 8:00AM CDT
The medical device majors struggling with their core businesses are often on the lookout for emerging therapies through acquisitions and alliances.
ABT: 41.97 (-0.50), JNJ: 123.00 (+0.08), ZBH: 125.57 (+0.11), LDRH: 36.98 (-0.02), MDT: 88.75 (-0.17), TMO: 154.80 (+0.42), STJ: 80.45 (-0.43), HTWR: 57.64 (-0.04), XRAY: 62.98 (-0.15), NUVA: 61.42 (+0.42), FEIC: 106.68 (-0.09)
FDA approves first dissolving stent for US patients
By MATTHEW PERRONE - AP - Tue Jul 05, 4:30PM CDT
WASHINGTON (AP) — A medical implant that slowly dissolves into the body could be the answer to long-standing safety concerns with devices used to treat clogged arteries.
BSX: 23.63 (-0.01), ABT: 41.97 (-0.50), MDT: 88.75 (-0.17)
Global Gonorrhea Diagnostics Market Growth of 9.25% CAGR by 2020 - Analysis, Technologies & Forecasts Report 2016-2020 - Key Vendors: Abbott Labs, Beckman Coulter, Roche Diagnostics - Research and Markets
BusinessWire - Mon Jul 04, 10:55AM CDT
Research and Markets has announced the addition of the "Global Gonorrhea Diagnostics Market 2016-2020" report to their offering.
ABT: 41.97 (-0.50)
Research Report Initiated on Select Medical Appliances & Equipment Equities
ACCESSWIRE - Thu Jun 30, 8:15AM CDT
LONDON, UK / ACCESSWIRE / June 30, 2016 / Active Wall St announces the list of stocks for today's research coverage. Pre-market the Active Wall St. team provides the latest corporate, market and technical events impacting selected stocks on the Medical Appliances & Equipment industry. Companies recently under review include Boston Scientific, Abbott Laboratories, Medtronic, and Hologic. See our complete report on Boston Scientific at:
BSX: 23.63 (-0.01), ABT: 41.97 (-0.50), MDT: 88.75 (-0.17), HOLX: 35.80 (+0.09)
Medical Laboratory Testing Services: Market Trends and Forecasts 2016-2019 - Latin America, Africa & Middle East Version - Key Vendors: Abbott Labs, Cartagenia, Firefly Bioworks - Research and Markets
BusinessWire - Tue Jun 28, 12:14PM CDT
Research and Markets has announced the addition of the "Medical Laboratory Testing Services: Market Trends and Forecasts 2016-2019 - Latin America, Africa & Middle East Version" report to their offering.
ABT: 41.97 (-0.50)
Glucose Health Type-2 Diabetes Product Now Available At Walmart
ACCESSWIRE - Tue Jun 28, 6:30AM CDT
BENTONVILLE, AR / ACCESSWIRE / June 28, 2016 / Glucose Health, Inc. (OTC: GLUC) today confirmed its dietary supplement formulated for persons with pre and Type-2 diabetes, Glucose Health® Daily Blood Sugar Maintenance, is now stocked and available for purchase in the "Diabetes Supplies" section at most Walmart pharmacies nationwide, as well as online at walmart.com
ABT: 41.97 (-0.50)
Mylan Launches Generic Version of Glaxo's Avodart in U.S.
Zacks Equity Research - Zacks Investment Research - Mon Jun 27, 4:31PM CDT
Mylan N.V. (MYL) announced that it has launched dutasteride capsules, 0.5 mg, the generic version of GlaxoSmithKline's (GSK) Avodart.
ABT: 41.97 (-0.50), JNJ: 123.00 (+0.08), MYL: 45.30 (+0.14), GSK: 43.75 (+0.03), BMY: 76.58 (+0.38)
Abbott Laboratories Falls 2.39% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Mon Jun 27, 1:28PM CDT
Abbott Laboratories (NYSE:ABT) traded in a range yesterday that spanned from a low of $36.76 to a high of $37.58. Yesterday, the shares fell 2.4%, which took the trading range below the 3-day low of $37.72 on volume of 5.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ABT: 41.97 (-0.50)
Covered Call reports for Apple, SolarCity, Skyworks Solutions, NVIDIA, and Abbott Laboratories include trade ideas that offer returns of 20% or more!
PR Newswire - Thu Jun 23, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for AAPL, ABT, NVDA, SCTY, and SWKS.
ABT: 41.97 (-0.50), SWKS: 65.35 (-0.45), SCTY: 24.22 (-0.39), AAPL: 96.87 (-0.55), NVDA: 52.78 (-0.02)
Abbott Hosts Conference Call for Second-Quarter Earnings
PR Newswire - Wed Jun 22, 8:00AM CDT
Abbott (NYSE: ABT) will announce its second-quarter 2016 financial results on Wednesday, July 20, 2016, before the market opens.
ABT: 41.97 (-0.50)
Epizyme Offers Early Data on Non-Hodgkin Lymphoma Drug
Zacks Equity Research - Zacks Investment Research - Mon Jun 20, 2:05PM CDT
Epizyme, Inc. (EPZM) reported encouraging preliminary data from its ongoing, global phase II trial on lead pipeline candidate, tazemetostat, at the American Society of Hematology Meeting on Lymphoma Biology.
ABT: 41.97 (-0.50), PFE: 36.31 (+0.07), EPZM: 9.78 (-0.77), BMY: 76.58 (+0.38)
Global Enteral Feeding Devices Market Growth of 5.5% CAGR by 2021 - Analysis, Technologies & Forecasts Report 2016-2021 - Key Vendors: Abbott Labs, Conmed Corp, Moog - Research and Markets
BusinessWire - Mon Jun 20, 1:31PM CDT
Research and Markets has announced the addition of the "Enteral Feeding Devices Market by Product (Feeding Pump, Feeding Tube, Giving Set, Enteral Syringes), Stage (Adult, Pediatrics), Application (Oncology, Gastroenterology, Neurology), End User (Hospital, Ambulatory Care) - Global Forecast to 2021" report to their offering.
ABT: 41.97 (-0.50), MOG.A: 54.63 (-0.36)
Global Biomarkers Market Worth USD 92.5 Billion by 2025 - Analysis, Technologies & Forecasts Report 2016-2025 - Key Vendors: Abbott Labs, Agilent Technologies, Bio-Rad Labs - Research and Markets
BusinessWire - Fri Jun 17, 3:01PM CDT
Research and Markets has announced the addition of the "Global Biomarkers Market Analysis & Trends - Industry Forecast to 2025" report to their offering.
ABT: 41.97 (-0.50), A: 46.41 (-0.12)
Global Patient Monitoring Devices Market Worth USD 33.9 Billion by 2025 - Analysis, Technologies & Forecasts Report 2016-2025 - Key Vendors: Abbott Labs, Omron Healthcare, Masimo Corp - Research and Markets
BusinessWire - Fri Jun 17, 2:40PM CDT
Research and Markets has announced the addition of the "Global Patient Monitoring Devices Market Analysis & Trends - Industry Forecast to 2025" report to their offering.
ABT: 41.97 (-0.50), MASI: 52.67 (+0.15)
The New #64 Most Shorted S&P 500 Component: Abbott Laboratories
MarketNewsVideo.com - Wed Jul 13, 3:27PM CDT
The most recent short interest data has been released for the 06/30/2016 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the S&P 500 by "days to cover." There are a...
ABT: 41.97 (-0.50)
Pfizer (PFE) Gets FDA Nod for Label Expansion of Prevnar 13
Zacks Equity Research - Zacks Investment Research - Wed Jul 13, 8:25AM CDT
Pfizer Inc. (PFE) announced that the FDA has approved a label expansion of vaccine Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]).
ABT: 41.97 (-0.50), JNJ: 123.00 (+0.08), PFE: 36.31 (+0.07)
Pfizer Reports Positive Data on Kidney Cancer Drug Sutent
Zacks Equity Research - Zacks Investment Research - Mon Jul 11, 8:23AM CDT
Pfizer Inc. (PFE) announced positive results from the phase III study, S-TRAC, on kidney cancer drug Sutent.
ABT: 41.97 (-0.50), PFE: 36.31 (+0.07), EXEL: 8.04 (-0.10), NVS: 82.03 (+0.35)
Shire (SHPG) Gets EU Nod for Label Expansion of Revestive
Zacks Equity Research - Zacks Investment Research - Fri Jul 08, 5:36PM CDT
Shire plc (SHPG) announced that the European Commission has granted an extension of the market authorization for its gastrointestinal drug (GI) Revestive for use in the pediatric population.
ABT: 41.97 (-0.50), JNJ: 123.00 (+0.08), SHPG: 192.49 (-2.82), PFE: 36.31 (+0.07)
Top 7 Research Reports for July 8, 2016
Sheraz Mian - Zacks Investment Research - Fri Jul 08, 12:16PM CDT
Top 7 Research Reports for July 8, 2016
ABT: 41.97 (-0.50), WBA: 81.77 (+0.55), IR: 67.52 (+0.58), MCD: 122.82 (+0.57), LOW: 81.65 (-1.29), BMY: 76.58 (+0.38)
Abbott Labs' Absorb Stent Gets Regulatory Approval in U.S.
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 8:58AM CDT
Abbott Laboratories (ABT) received a major boost when the FDA approved its bioresorbable heart stent, Absorb, for the treatment of coronary artery disease in the U.S.
ABT: 41.97 (-0.50), JNJ: 123.00 (+0.08), PFE: 36.31 (+0.07), STJ: 80.45 (-0.43)
Medical Device Consolidation Frenzy: Here's How to Play it
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 8:00AM CDT
The medical device majors struggling with their core businesses are often on the lookout for emerging therapies through acquisitions and alliances.
ABT: 41.97 (-0.50), JNJ: 123.00 (+0.08), ZBH: 125.57 (+0.11), LDRH: 36.98 (-0.02), MDT: 88.75 (-0.17), TMO: 154.80 (+0.42), STJ: 80.45 (-0.43), HTWR: 57.64 (-0.04), XRAY: 62.98 (-0.15), NUVA: 61.42 (+0.42), FEIC: 106.68 (-0.09)
FDA approves first dissolving stent for US patients
By MATTHEW PERRONE - AP - Tue Jul 05, 4:30PM CDT
WASHINGTON (AP) — A medical implant that slowly dissolves into the body could be the answer to long-standing safety concerns with devices used to treat clogged arteries.
BSX: 23.63 (-0.01), ABT: 41.97 (-0.50), MDT: 88.75 (-0.17)
Global Gonorrhea Diagnostics Market Growth of 9.25% CAGR by 2020 - Analysis, Technologies & Forecasts Report 2016-2020 - Key Vendors: Abbott Labs, Beckman Coulter, Roche Diagnostics - Research and Markets
BusinessWire - Mon Jul 04, 10:55AM CDT
Research and Markets has announced the addition of the "Global Gonorrhea Diagnostics Market 2016-2020" report to their offering.
ABT: 41.97 (-0.50)
Research Report Initiated on Select Medical Appliances & Equipment Equities
ACCESSWIRE - Thu Jun 30, 8:15AM CDT
LONDON, UK / ACCESSWIRE / June 30, 2016 / Active Wall St announces the list of stocks for today's research coverage. Pre-market the Active Wall St. team provides the latest corporate, market and technical events impacting selected stocks on the Medical Appliances & Equipment industry. Companies recently under review include Boston Scientific, Abbott Laboratories, Medtronic, and Hologic. See our complete report on Boston Scientific at:
BSX: 23.63 (-0.01), ABT: 41.97 (-0.50), MDT: 88.75 (-0.17), HOLX: 35.80 (+0.09)
Medical Laboratory Testing Services: Market Trends and Forecasts 2016-2019 - Latin America, Africa & Middle East Version - Key Vendors: Abbott Labs, Cartagenia, Firefly Bioworks - Research and Markets
BusinessWire - Tue Jun 28, 12:14PM CDT
Research and Markets has announced the addition of the "Medical Laboratory Testing Services: Market Trends and Forecasts 2016-2019 - Latin America, Africa & Middle East Version" report to their offering.
ABT: 41.97 (-0.50)
Glucose Health Type-2 Diabetes Product Now Available At Walmart
ACCESSWIRE - Tue Jun 28, 6:30AM CDT
BENTONVILLE, AR / ACCESSWIRE / June 28, 2016 / Glucose Health, Inc. (OTC: GLUC) today confirmed its dietary supplement formulated for persons with pre and Type-2 diabetes, Glucose Health® Daily Blood Sugar Maintenance, is now stocked and available for purchase in the "Diabetes Supplies" section at most Walmart pharmacies nationwide, as well as online at walmart.com
ABT: 41.97 (-0.50)
Mylan Launches Generic Version of Glaxo's Avodart in U.S.
Zacks Equity Research - Zacks Investment Research - Mon Jun 27, 4:31PM CDT
Mylan N.V. (MYL) announced that it has launched dutasteride capsules, 0.5 mg, the generic version of GlaxoSmithKline's (GSK) Avodart.
ABT: 41.97 (-0.50), JNJ: 123.00 (+0.08), MYL: 45.30 (+0.14), GSK: 43.75 (+0.03), BMY: 76.58 (+0.38)
Abbott Laboratories Falls 2.39% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Mon Jun 27, 1:28PM CDT
Abbott Laboratories (NYSE:ABT) traded in a range yesterday that spanned from a low of $36.76 to a high of $37.58. Yesterday, the shares fell 2.4%, which took the trading range below the 3-day low of $37.72 on volume of 5.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ABT: 41.97 (-0.50)
Covered Call reports for Apple, SolarCity, Skyworks Solutions, NVIDIA, and Abbott Laboratories include trade ideas that offer returns of 20% or more!
PR Newswire - Thu Jun 23, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for AAPL, ABT, NVDA, SCTY, and SWKS.
ABT: 41.97 (-0.50), SWKS: 65.35 (-0.45), SCTY: 24.22 (-0.39), AAPL: 96.87 (-0.55), NVDA: 52.78 (-0.02)
Abbott Hosts Conference Call for Second-Quarter Earnings
PR Newswire - Wed Jun 22, 8:00AM CDT
Abbott (NYSE: ABT) will announce its second-quarter 2016 financial results on Wednesday, July 20, 2016, before the market opens.
ABT: 41.97 (-0.50)
Epizyme Offers Early Data on Non-Hodgkin Lymphoma Drug
Zacks Equity Research - Zacks Investment Research - Mon Jun 20, 2:05PM CDT
Epizyme, Inc. (EPZM) reported encouraging preliminary data from its ongoing, global phase II trial on lead pipeline candidate, tazemetostat, at the American Society of Hematology Meeting on Lymphoma Biology.
ABT: 41.97 (-0.50), PFE: 36.31 (+0.07), EPZM: 9.78 (-0.77), BMY: 76.58 (+0.38)
Global Enteral Feeding Devices Market Growth of 5.5% CAGR by 2021 - Analysis, Technologies & Forecasts Report 2016-2021 - Key Vendors: Abbott Labs, Conmed Corp, Moog - Research and Markets
BusinessWire - Mon Jun 20, 1:31PM CDT
Research and Markets has announced the addition of the "Enteral Feeding Devices Market by Product (Feeding Pump, Feeding Tube, Giving Set, Enteral Syringes), Stage (Adult, Pediatrics), Application (Oncology, Gastroenterology, Neurology), End User (Hospital, Ambulatory Care) - Global Forecast to 2021" report to their offering.
ABT: 41.97 (-0.50), MOG.A: 54.63 (-0.36)
Global Biomarkers Market Worth USD 92.5 Billion by 2025 - Analysis, Technologies & Forecasts Report 2016-2025 - Key Vendors: Abbott Labs, Agilent Technologies, Bio-Rad Labs - Research and Markets
BusinessWire - Fri Jun 17, 3:01PM CDT
Research and Markets has announced the addition of the "Global Biomarkers Market Analysis & Trends - Industry Forecast to 2025" report to their offering.
ABT: 41.97 (-0.50), A: 46.41 (-0.12)
Global Patient Monitoring Devices Market Worth USD 33.9 Billion by 2025 - Analysis, Technologies & Forecasts Report 2016-2025 - Key Vendors: Abbott Labs, Omron Healthcare, Masimo Corp - Research and Markets
BusinessWire - Fri Jun 17, 2:40PM CDT
Research and Markets has announced the addition of the "Global Patient Monitoring Devices Market Analysis & Trends - Industry Forecast to 2025" report to their offering.
ABT: 41.97 (-0.50), MASI: 52.67 (+0.15)
